List view / Grid view
17 March 2016 | By Victoria White
A jury has delivered a verdict in Amgen's favour in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to PCSK9...
11 March 2016 | By Victoria White
A Phase III study demonstrated that sarilumab was superior to adalimumab in improving signs and symptoms in patients with active RA...
4 March 2016 | By Victoria White
Sanofi Genzyme says the safety and efficacy data from the NEO1 study support further development of neoGAA...
23 February 2016 | By Victoria White
This NDA submission is based on data from two Phase 3 studies of insulin glargine and lixisenatide in patients with with type 2 diabetes...
12 February 2016 | By Victoria White
Heart UK has questioned why the NICE did not seek the expertise of lipidologists during its latest review of PCSK9 cholesterol-busting drugs...
8 February 2016 | By Victoria White
NICE was concerned that alirocumab had not been compared with the combination therapy of ezetimibe plus a statin and that trials of the drug were not able to provide robust information on cardiovascular outcomes...
5 February 2016 | By Victoria White
Mr. Mansuri joins Sanofi from Gilead Sciences and will take the position of Executive Vice President, Strategy & Business Development...
15 December 2015 | By Victoria White
The proposed transaction would consist of an exchange of Sanofi animal health business (Merial) and Boehringer Ingelheim consumer healthcare (CHC) business...
6 November 2015 | By Victoria White
Sotagliflozin is an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 which could be a potential treatment option for people with diabetes...
5 November 2015 | By Victoria White
Sanofi and Hanmi have entered a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments...
29 September 2015 | By Victoria White
The NDA submission for lixisenatide is based on results from the GetGoal clinical programme and includes findings from the recently-completed ELIXA study...
28 September 2015 | By Victoria White
Praluent is the only EC-approved PCSK9 inhibitor that is available in two starting doses, offering two levels of efficacy...
14 September 2015 | By Victoria White
The fixed-ratio combination of insulin glargine and lixisenatide, a GLP-1 receptor agonist, demonstrated statistically superior reduction in HbA1c compared with insulin glargine alone...
26 August 2015 | By Victoria White
The US Food and Drug Administration (FDA) has approved Praluent (alirocumab) Injection - the first and only PCSK9 inhibitor approved in the US...
4 August 2015 | By Victoria White
Toujeo is now available in the UK, providing another option for adults with type 1 and type 2 diabetes mellitus to help manage their condition...
